# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Morgan Stanley analyst Matthew Harrison maintains IO Biotech (NASDAQ:IOBT) with a Overweight and raises the price target fro...
HC Wainwright & Co. analyst Emily Bodnar reiterates IO Biotech (NASDAQ:IOBT) with a Buy and maintains $12 price target.
Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous C...
Piper Sandler analyst Christopher Raymond maintains IO Biotech (NASDAQ:IOBT) with a Overweight and maintains $10 price target.